ePrints

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Lookup NU author(s): Dr Massimo Younes, Dr Olivier GovaereORCiD, Dr Dina Tiniakos, Professor Alastair BurtORCiD, Marco Zaki, Professor Quentin AnsteeORCiD

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Abstract

INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

Publication metadata

Author(s): Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E

Publication type: Article

Publication status: Published

Journal: American Journal of Gastroenterology

Year: 2020

Volume: 115

Issue: 8

Pages: 1289-1292

Print publication date: 01/08/2020

Acceptance date: 02/04/2018

Date deposited: 22/10/2020

ISSN (print): 0002-9270

ISSN (electronic): 1572-0241

Publisher: Lippincott, Williams & Wilkins

URL: https://doi.org/10.14309/ajg.0000000000000676

DOI: 10.14309/ajg.0000000000000676

PubMed id: 32453041

Altmetrics

Funding

Share